🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 20 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/03/2019 36,06 38,03 35,75 36,94 +2,19% 6,32% 888.500
15/03/2019 35,51 36,47 35,34 36,15 +2,61% 3,18% 1.799.300
14/03/2019 35,05 35,66 34,84 35,23 +0,51% 2,34% 512.300
13/03/2019 34,90 35,14 34,09 35,05 +0,95% 3,01% 477.000
12/03/2019 34,82 35,32 34,32 34,72 -0,29% 2,87% 546.300
11/03/2019 33,62 34,84 32,96 34,82 +3,69% 5,59% 565.800
08/03/2019 33,43 33,68 32,85 33,58 +0,48% 2,48% 487.300
07/03/2019 33,97 33,97 33,00 33,42 -1,30% 2,86% 579.000
06/03/2019 34,60 35,24 33,86 33,86 -3,23% 3,99% 801.400
05/03/2019 34,65 35,87 33,74 34,99 +0,98% 6,15% 767.000
04/03/2019 35,65 36,25 34,04 34,65 -2,56% 6,19% 1.100.700
01/03/2019 33,03 35,62 32,10 35,56 +2,95% 10,66% 1.141.000
28/02/2019 35,34 35,41 33,90 34,54 -1,96% 4,27% 808.300
27/02/2019 34,15 35,41 34,15 35,23 +2,98% 3,69% 718.300
26/02/2019 33,52 34,27 32,91 34,21 +1,30% 4,07% 674.900
25/02/2019 33,34 34,80 33,07 33,77 +2,52% 5,19% 1.120.200
22/02/2019 31,64 33,26 31,05 32,94 +5,00% 6,98% 1.125.100
21/02/2019 30,95 31,54 30,16 31,37 +0,77% 4,46% 1.056.500
20/02/2019 29,79 31,33 29,60 31,13 +4,53% 5,81% 1.930.400
19/02/2019 29,69 30,54 29,64 29,78 +0,34% 3,03% 785.000
15/02/2019 29,20 29,74 29,06 29,68 +2,17% 2,33% 805.100
14/02/2019 29,67 29,83 28,97 29,05 -2,19% 2,90% 481.600
13/02/2019 30,73 31,01 29,61 29,70 -2,33% 4,56% 624.900
12/02/2019 30,12 30,98 29,92 30,41 +1,74% 3,52% 802.500
11/02/2019 29,89 30,27 29,64 29,89 +0,57% 2,11% 306.500
08/02/2019 29,50 30,09 29,46 29,72 +0,64% 2,14% 581.400
07/02/2019 29,77 30,51 29,15 29,53 -1,86% 4,55% 766.900
06/02/2019 30,50 30,85 30,00 30,09 -1,34% 2,79% 530.000
05/02/2019 30,84 31,60 30,32 30,50 -0,68% 4,15% 852.200
04/02/2019 30,85 31,37 30,58 30,71 -0,68% 2,56% 465.800